GSK: FDA approves monthly injection for HIV treatment

(CercleFinance.com) - The Food and Drug Administration approved a once-a-month HIV treatment that was developed by ViiV Healthcare, the specialist HIV unit of Britain's GlaxoSmithKline.


Cabenuva, a long-acting therapy which is provided as a pack of two injectable medicines - ViiV Healthcare's cabotegravir and Janssen's rilpivirine - is taken once a month, replacing current antiretroviral pills that have to be taken daily.

"Cabenuva reduces the treatment dosing days from 365 days to 12 days per year," said Lynn Baxter, the head of ViiV for North America.

Not only the drug results in a reduction in the frequency of dosing, but it was also preferred by most clinical trial participants compared to their prior daily oral regimens, researchers said.

Copyright (c) 2021 CercleFinance.com. All rights reserved.